Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Melphalan

A new hybrid medicine is intended for the treatment of certain haematological and other cancers and as reduced intensity conditioning treatment prior to allo-HSCT in haematological diseases
01 Oct 2020
Anticancer agents & Biologic therapy;  Breast cancer;  Gynaecologic malignancies;  Haematologic malignancies

On 17 September 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product melphalan (Phelinun), intended for the treatment of certain haematological and other cancers and as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in haematological diseases in adults and children. 

The applicant for this medicinal product is ADIENNE S.r.l. S.U. 

Phelinun will be available as 50-mg and 200-mg powder and solvent for concentrate for solution for infusion. The active substance of Phelinun is melphalan, an anti-neoplastic agent (ATC code: L01AA03) which prevents the separation and replication of DNA, thereby preventing cell replication. 

The benefits of Phelinun from published studies in adults and children include increased overall survival, diseasefree survival, eventfree survival and nonrelapse mortality.  

The most common side effects are myelosuppression and haematological toxicities, gastrointestinal toxicity and immune system disorders. Amenorrhoea, ovarian disorders and premature menopause were also commonly reported. Infections, acute and chronic graft-versus-host disease were reported as the major causes of morbidity and mortality in the allo-HSCT setting.  

Phelinun is a hybrid medicine of Alkeran which has been authorised in the EU since 1996. Phelinun contains the same active substance as Alkeran but is intended for an additional indication based on published literature. 

Studies have demonstrated the satisfactory quality of Phelinun. Since Phelinun is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Alkeran was not required. 

The full indications are: 

High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of: 

  • multiple myeloma 

  • malignant lymphoma (Hodgkin, non-Hodgkin lymphoma) 

  • acute lymphoblastic and myeloblastic leukemia 

  • childhood neuroblastoma 

  • ovarian cancer 

  • mammary adenocarcinoma. 

Phelinun in combination with other cytotoxic medicinal products is indicated as RIC treatment prior to allo-HSCT in malignant haematological diseases in adults. 

Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allo-HSCT in haematological diseases in the paediatric population as: 

  • Myeloablative conditioning treatment in case of malignant haematological diseases 

  • RIC treatment in case of non-malignant haematological diseases. 

Phelinun should be prescribed by physicians experienced in the treatment of cancer. 

Detailed recommendations for the use of this product will be described in the Summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission. 

Hybrid applications rely in part on the results of pre-clinical tests and clinical trials for a reference product and in part on new data. 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings